Mas...Hacerse con Avastin estaba entre uno de los principales objetivos en las largas negociaciones entre Roche y Genentech. Ahora, una vez materializada la fusión, las cosas parecen no salir como se deseaban.
Roche has announced that Avastin combined with chemotherapy to treat colon cancer has failed to reach its primary endpoint of lowering the risk of the cancer returning in a phase III trial. The study, known as NSABP C-08, monitored the use of Avastin with chemotherapy for treatment of colon cancer after surgery compared with chemotherapy alone.
Dr Hal Barron, senior vice president, Development and chief medical officer of Genentech said: "While we are disappointed the C-08 study did not meet its primary endpoint, our initial review of the data leads us to continue to believe Avastin may be active in patients with early-stage colon cancer and look forward to NSABP's presentation at ASCO [American Society of Clinical Oncology]".
Genentech gets the last laugh with Roche?
April 23, 2009
One of the pivotal negotiating points of the longstanding acquisition of Genentech by Roche was the forthcoming study of Avastin in colon cancer. The Avastin trial was widely reported as a key element to the negotiations. As Roche & Genentech openly debated a fair value for DNA shares, both sides played the PR game as the trials data was expected to be released this spring.
Entradas
No hay comentarios:
Publicar un comentario